Coronavirus

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the...

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)

-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including...

UPDATE — Institutional Shareholder Services Inc. Recommends Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy

ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE...

Institutional Shareholder Services Inc. Recommends Senova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy

ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE...

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism

OncoBay Clinical is a boutique clinical research organization (CRO) that is a subsidiary of the Moffitt Cancer Center and has...

Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data

In IND-enabling studies, HSB-1216 remained tightly bound within the Quatramer™ until reaching its tumor target, consistent with earlier pre-clinical studies...

error: Content is protected !!